Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...

There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing “extremely ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.